Shimadzu launches new inert UHPLC - Nexera XS
Sep 27 2022
Shimadzu, a global leader in analytical instrumentation, has announced the release of the new Nexera XS inert, a bioinert and biocompatible Ultra-High Performance Liquid Chromatograph (UHPLC). The system has been designed to resolve the most common problems encountered in the analysis of biopharmaceuticals, such as the adsorption of target molecules to metal surfaces and corrosion due to mobile phases with high salt content and extreme pH conditions.
The new Nexera XS inert UHPLC features a metal-free sample flow path that prevents unwanted interaction with biopolymers prone to adsorption onto exposed metal sites. By doing this, the Nexera XS inert achieves reduced sample loss and excellent peak shape with reproducibly high sensitivity, high-quality and reliable data. In addition, all wetted surfaces are prepared from corrosion-resistant materials, rendering them stable against mobile phase solvents containing high concentrations of salts or acids.
Nexera XS inert offers the same superior reliability, robustness and expandability as the other UHPLC systems in the Nexera series. It is particularly well-suited to the analysis of biopolymers such as antibodies, peptides and nucleic acid drugs.
All valves used in Nexera XS inert system are designed to inhibit metal adsorption. That ensures worry-free switching between multiple columns for method development or for trap-and-elute analysis without adsorption concerns.
The Nexera XS inert is also equipped with additional new and advanced product features, such as bioinert column switching, tool-free UHPLC connectors and a real-time pH monitor.
For more details visit our website.
In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Oct 09 2022 New Orleans, LA, USA
Oct 11 2022 Lisbon, Portugal
Oct 12 2022 Telford, UK
Oct 23 2022 Hangzhou, China & Virtual
Nov 09 2022 Cleveland, OH, USA